Liver resection is the goal of treatment strategies for liver-confined metastatic colorectal cancer. However, after resection the majority of patients will experience recurrence. Chemotherapy seems to improve outcomes compared with surgery alone. We reviewed the data of the role of adjuvant chemotherapy after resection of liver-confined metastatic colorectal cancer. Optimal regimens and sequencing of chemotherapies when liver resection is an option are unclear. Some suggest that resectable liver metastases, in the absence of high-risk features, should begin with surgery and consideration given to adjuvant chemotherapy after surgery. If high-risk features are present, most physicians prefer a short course of systemic preoperative chemotherapy. Perioperative therapy and regional therapy with hepatic arterial infusion (HAI) both increase disease-free survival (DFS) when compared with surgery alone. In unresectable disease, consideration should be given to systemic chemotherapy with or without a biologic agent or HAI with systemic therapy. If the disease becomes resectable, adjuvant treatment should follow surgery. Adjuvant chemotherapy is usually FOLFOX, but HAI combined with systemic chemotherapy is also an option. The role of adjuvant treatment post-liver resection should not be viewed in isolation but rather in the context of prior treatment, surgical preference, and individual patient characteristics. Perioperative therapy and regional therapy have both shown an increase in DFS. Conducting randomized trials examining the role of adjuvant chemotherapy has been difficult because of rapidly changing chemotherapies.
INTRODUCTION
Colorectal cancer (CRC) is a major cause of cancerrelated mortality worldwide with approximately 500,000 deaths annually. In Western countries, CRC is the second most frequent cause of cancer-related mortality.
1-3 At diagnosis, 15% to 20% of patients will have synchronous liver metastases and at least another 60% who develop metastatic disease will have liver metastases. [4] [5] [6] Portal venous drainage of the colon to the liver may explain this pattern of metastatic spread.
Tandem developments in surgery and chemotherapy have resulted in significant improvements in overall survival (OS) for patients with metastatic CRC over the past decade. 7 For patients who can have liver metastases resected, 5-year survival rates are 30% to 40%, with 20% alive at 10 years. [8] [9] [10] Thus, hepatic resection is now an accepted standard despite lack of randomized data. 11 However, most patients who present with liver metastases will have initially unresectable disease.
12 Combination chemobiologic therapy and regional therapy can downstage some patients allowing conversion to resectable disease. [13] [14] [15] [16] [17] This review will discuss the rationale for and data supporting adjuvant (postoperative) chemotherapy after liver resection. 18, 19 Neoadjuvant (preoperative) and perioperative chemotherapy, common strategies used for CRC liver metastases, are also discussed and relative merits compared with adjuvant treatment.
PREDICTION OF SURVIVAL AFTER LIVER RESECTION
Several retrospective series have reported scoring systems predicting recurrence after liver resection. Nordlinger et al 20 reported a prognostic scoring system derived from a 1,569 patient series who underwent liver resection. Survival was affected by age (Ͼ 60 years), size of the largest liver metastasis (Ͼ 5 cm), disease-free interval between primary tumor and liver metastases (Ͻ 2 years), number of liver metastases (Ͼ 1), and resection margin. In another 1,001 patient series reported at Memorial SloanKettering Cancer Center (MSKCC), 21 independent predictors of poor long-term outcome were positive resection margin, extrahepatic disease, nodepositive primary, disease-free interval from primary to metastases (Ͻ 12 months), number of hepatic tumors (Ͼ 1), largest hepatic tumor (Ͼ 5 cm), and carcinoembryonic antigen level (Ͼ 200 ng/mL). When the last five criteria were used in a preoperative scoring system (clinical risk score [CRS] ), assigning one point for each criterion, total score was highly predictive of outcome (P Ͻ .001). Patients with CRS 0 had a 60% 5-year actuarial survival rate versus 14% for CRS 5. 21 The authors subsequently developed a nomogram predicting disease-specific survival after hepatic resection to help stratify patients for adjuvant clinical trials. 22 Other series have reported similar scoring systems using various clinicopathologic variables (eg, TN stage of primary tumor, number and size of liver metastases) and blood tests (eg, preoperative carcinoembryonic antigen levels). 5, [23] [24] [25] Molecular analyses may also affect recurrence and survival. Defects in DNA mismatch repair may have implications for response to fluorouracil (FU) and irinotecan-based chemotherapy as well as overall survival. 26 Tumoral BRAF mutations, high cyclin D1, high survivin mRNA, and high tumoral thymidylate synthase have all been associated with poor outcome. [27] [28] [29] [30] Integration of these and other biomarkers into adjuvant protocols should be considered.
EVIDENCE FOR ADJUVANT SYSTEMIC TREATMENT AFTER LIVER RESECTION
Recurrence after liver resection is a significant problem with nearly 70% of patients developing recurrence in hepatic or extra-hepatic sites. Thus, there is a rationale for adjuvant chemotherapy after liver resection. Up to 50% of recurrences are in the liver with the majority in the first 2 years postresection. [31] [32] [33] In four randomized trials, liver resection was followed by adjuvant systemic chemotherapy or observation. [34] [35] [36] [37] Two trials included less than 52 patients and were inadequately powered. 34, 36 [OR] for death in the chemotherapy arm was 0.73; 95% CI, 0.48 to 1.10, P ϭ .13).
37 On recurrence, second-line chemotherapy was given to 85% of patients in treatment and control arms. The end point was DFS and the intention-to-treat population univariate analysis failed to show benefit (5-year DFS, 33.5% v 26.7% in treated and control arms, respectively). Only after adjusting for negative prognostic factors (eg, synchronous and multiple metastases) was a significant DFS benefit effect seen for chemotherapy (OR for recurrence or death, 0.66; 95% CI, 0.46 to 0.96; P ϭ .028). Grade 3 to 4 toxicities were reported in 25% of patients in the treatment arm and included hematologic (n ϭ 6) and diarrhea (n ϭ 7). The small numbers accrued over 10 years and the now-outdated chemotherapy used, highlight the difficulties in conducting an adjuvant study after liver resection.
Mitry et al 12 performed a meta-analysis of 278 patients from the two trials above (ENG trial 35 and FFCD-ACHBTH-ARUC trial
37
). Median progression-free survival (PFS) of 27.9 versus 18.8 months for adjuvant bolus FU/LV and surgery-alone arms, respectively (hazard ratio [HR], 1.32; 95% CI, 1.00 to 1.76; P ϭ .058), was reported. Median survival was 62.2 and 47.3 months in the chemotherapy versus surgery-alone arms, respectively (HR, 1.32; 95% CI, 0.95 to 1.82; P ϭ .095; Appendix Fig A1, online only) . In multivariate analysis, adjuvant chemotherapy was independently associated with PFS (P ϭ .036) and OS (P ϭ .046). The number of metastases (Ն 2) was also associated with survival (P ϭ .023).
Several retrospective series have shown benefit for adjuvant treatment after liver resection. Parks et al 11 reported an analysis of 792 patients who had liver resections between 1991 and 1998. A minority (34%) of patients received FU-based adjuvant chemotherapy. Multivariate analysis showed positive margins (HR, 1.59), bilateral liver tumors (HR, 1.39), and adjuvant chemotherapy (HR, 0.75) as independent predictors of outcome (P Ͻ .01 for each 38 Receiving chemotherapy (regimens not cited) was independently associated with overall recurrence-free survival (HR, 0.56; 95% CI, 0.33 to 0.65; P Ͻ .009).
The addition of modern chemotherapy to the FU/LV backbone is being studied in the adjuvant setting after liver resection. A European study randomly assigned 151 patients to bolus/infusional FU/LV or FOLFIRI (irinotecan and bolus/infusional FU/LV) after resection.
38
With a primary end point of DFS and median follow-up of 42 months, median DFS was 21.6 and 24.7 months for the FU/LV and FOLFIRI groups, respectively (P ϭ .47). On multivariate analysis, adverse factors associated with DFS included prior adjuvant chemotherapy for the primary tumor, liver metastases Յ 1 year after the primary cancer, and more than one liver lesion. Grade 3 to 4 toxicity was more common in patients treated with FOLFIRI versus FU/LV (47% v 30%). As yet there are no randomized data to support adjuvant oxaliplatinbased chemotherapy alone after liver resection, although a Japanese randomized trial 42 comparing modified FOLFOX6 (oxaliplatin and bolus/infusional FU/LV) with surgery alone is currently accruing. A recent retrospective study from Korea compared outcomes of 156 patients who were treated with either FOLFOX (58 patients), FOLFIRI (28 patients), or fluoropyrimidines alone (50 patients) after liver resection. 43 After median follow-up of 3.7 years, there was a nonsignificant DFS difference among the three adjuvant regimens (P ϭ .088). Overall, 3-year DFS rate was 28.1%, and for each individual group 3-year DFS was 35% (FOLFOX), 25% (FOLFIRI), and 25% (fluoropyrimidines alone). After adjusting for adverse prognostic variables the difference between each group remained nonsignificant, trending toward greater benefit with FOLFOX (P ϭ .068). There was no significantOSdifference.Overalltherefore,theadministrationofchemotherapy, namely bolus FU/LV after liver metastases resection, trends to improve prognosis, but the benefit of adjuvant chemotherapy is not yet formally proven.
EVIDENCE FOR ADJUVANT HAI AFTER LIVER RESECTION
The majority of recurrences after liver resection are in the liver, and therefore, there has been interest in adjuvant HAI in this setting. Normal hepatic parenchyma derives most of its blood supply from the portal vein while liver metastases are supplied by the hepatic artery. 44 Prolonged, controlled infusion of chemotherapy directly into the hepatic artery with long-term catheter patency is possible via an implantable HAI pump.
45 Floxuridine (FUDR), a derivate of 5FU, has distinct pharmacologic and pharmacokinetic advantages for HAI administration (ie, high hepatic extraction, high total body clearance, short plasma half-life, and linear kinetics), thus allowing high-doses with minimal systemic toxicity. Ensminger 46 estimated a 400-fold advantage for FUDR when given via HAI route.
Five studies randomly assigned patients after liver resection to observation or adjuvant HAI plus systemic chemotherapy (SYS).
47-51
Two of the largest studies are in Table 2. 48,49,52-54 The Eastern Cooperative Oncology Group (ECOG) randomly assigned 109 patients to HAI plus SYS versus no further therapy. All patients had one to three resectable liver metastases. Only 75 patients were eligible. This study achieved its primary end point of increased DFS. In patients who were able to have pump therapy, the DFS at 4 years was 46% for the HAI group and 25% for surgery alone (P ϭ .04) with a trend toward improved OS at 4 years (62% v 53%, respectively; P ϭ .6). 48 Two thirds of patients completed four full courses of HAI therapy and 43% completed SYS. There was one postoperative death in each arm, grade 3 to 4 toxicities were seen in 50% of patients (all grade 3 except for grade 4 liver enzyme elevation seen in three patients [8%]). Two patients required biliary stenting. A German study (26 centers participated) accrued 226 patients. 49 Patients were treated via a port (which does not allow drug delivery for long periods) instead of an internal pump, and with FU which has less hepatic extraction compared with FUDR. 46, 55 In the treatment group, 11% of patients received no hepatic treatment, 5% were not resected, and only 30% completed chemotherapy. No improvement in median time to progression was seen at 18-month planned interim analysis. In treated patients, median PFS in the liver was 45 and 23 months, and median time to overall progression was 20 and 13 months for the HAI and control groups, respectively. Grade 3 to 4 toxicities, mostly stomatitis and nausea, were seen in 63% of patients. Higher toxicities were likely accounted for by less favorable pharmacokinetics of FU/LV given via HAI. Smaller studies showed a significant survival advantage for HAI, however, there is a lack of power in each study with only 30 to 40 patients randomly assigned. 47, 51, 56 Two studies compared HAI plus SYS to SYS alone after hepatic resection (Table 2) . [52] [53] [54] The MSKCC study randomly assigned 156 patients postresection to 6 months of HAI FUDR/ dexamethasone combined with SYS FU/LV (n ϭ 74) or SYS FU/LV alone (n ϭ 82).
52,53 There was no limit on the number of liver metastases; 27% of patients had more than four liver lesions and 13% had positive surgical margins after liver resection. The designated end point was 2-year survival, which was 86% and 72% (P ϭ .03) and hepatic DFS was 90% and 60% for HAI plus SYS and SYS arms, respectively (P Ͻ .001). In the HAI group, 26% of patients received more than 50% of the planned dose of FUDR (reductions due to liver enzyme changes) and 40% of patients received more than 90% of the planned dose of FU/LV. In the SYS alone arm, 48% of patients received more than 90% of planned FU/LV. Toxic effects of chemotherapy were similar in both arms except that more patients in the HAI arm experienced diarrhea. Three patients died on treatment (one in the HAI arm and two in the systemic arm). Grade 3 to 4 toxicity was mainly neutropenia (18% to 21%), diarrhea (14% to 29%), and stomatitis (9% to 11%). Eighteen percent of patients in the HAI arm had grade 3 bilirubin (Ͼ 3.0 mg/dL) and 5% (four patients) required biliary stenting. Two patients in the FU/LV arm also required biliary stents. Updated results with 10.3 years median follow-up and all patients observed for at least 6 years, reported a 10-year overall survival rate of 41% for the HAI plus SYS group versus 27.2% for the SYS group (P ϭ .10). Overall PFS was 31.3 months in the HAI group versus 17.2 months in the SYS group (P ϭ .02). Patients with high CRS (3 to 5) seemed to benefit more from HAI plus SYS with a 60-month median survival versus 38.3 months for SYS group. 11, 31, 53 Lygidakis et al 54 reported a trial of 122 patients randomly assigned to HAI plus SYS chemoimmunotherapy versus SYS chemoimmunotherapy alone after liver resection. Most patients (80%) were observed for at least 4 years, and 60% for longer than 6 years. There was a significant improvement in 4-year DFS (58% v 34%; P ϭ .002), and 4-year survival was 73% and 60% for HAI plus SYS and SYS alone groups, respectively (P ϭ .05). 54 Ninety percent of patients completed planned treatment in the HAI plus SYS arm compared with 70% of patients in the SYS only arm. Total chemotherapy dose in the HAI arm was split 50:50 between HAI and intravenous routes. Nonhepatic grade 3 to 4 toxicity (eg, neutropenia and diarrhea) was more common in the SYS arm (35% v 2%). Grade 3 to 4 hepatic toxicity was similar in both arms (10% v 7%).
Modern chemotherapy (ie, irinotecan and oxaliplatin) combined with HAI has shown promising results in single-institution studies with 5-year survival rates of at least 59% (Fig 1) . 57, 58 In a new study of 73 patients using HAI FUDR/dexamethasone plus SYS (oxaliplatin or irinotecan-based) with or without bevacizumab after resection of liver metastases, the 5-year survival was 87% (Kemeny et al, submitted for publication). Sixty percent of randomly assigned patients had more than three liver metastases. A pooled analysis of 236 patients from all four adjuvant MSKCC HAI studies showed that long-term survival was possible even in patients with CRS of 3 to 5 (5-year survival of 52%; Kemeny et al, submitted for publication). 53, 57, 58, 60 Alberts et al 61 reported interim results from the National Surgical Adjuvant Breast and Bowel Project C-09 study of systemic capecitabine and oxaliplatin alternating with HAI FUDR after resection of liver-confined colorectal cancer. The primary end point was 2-year survival. After median follow-up of 28 months, estimated 2-year survival was 88% and median survival was 46 months.
Retrospective studies have shown a benefit of HAI after liver resection. In a recent review of more than 1,000 patients resected at MSKCC between 1991 and 2002 (median follow-up 41 months), multivariate analysis demonstrated that one of the significant factors to improve survival was postoperative HAI therapy. Survival was significantly improved, 68 versus 50 months, for patients who received HAI versus those who did not (HR, 0.64; 95% CI, 0.51 to 0.81; P Ͻ .001).
62 Postoperative SYS alone (mostly bolus FU/LV) did not provide a significant OS or DFS benefit. House et al 63 reported on 250 patients who underwent resection between 2001 and 2005 and received either HAI with modern SYS or SYS alone (FOLFOX or FOLFIRI) in the adjuvant setting. Five-year survival in the HAI group was 72% versus 52% in the SYS alone group (P ϭ .004).
63 Meta-analyses and other retrospective series have also shown an OS and DFS benefit for HAI therapy in the adjuvant setting after liver resection. 10, 64, 65 Despite the prospective and retrospective data supporting HAI in the adjuvant setting after liver resection, this strategy has not been universally accepted. Requirement of surgical expertise for pump insertion, nuclear medicine albumin scan assessing pump perfusion, complicated treatment regimens, and specific toxicities related to HAI are some of the reasons why this strategy has not been universally accepted. Also, most physicians consider SYS (ie, FOLFOX) easier to administer then HAI therapy with more predictable and manageable adverse effect profile. Mediports are a requirement for administering FOLFOX or FOLFIRI and can be inserted by interventional radiology using local anesthesia. However, in retrospective series from MSKCC, the overall rate of pump complications is low at 22%, and the majority of these complications can be salvaged with 80% of pumps remaining functional for at least 2 years. Raised transaminase is not uncommon but raised bilirubin or alkaline phosphatase is more serious and continued elevation may indicate sclerosing cholangitis. The addition of dexamethasone to FUDR has decreased the incidence of this biliary toxicity. 66, 67 Increased bilirubin higher than 3.0 mg/dL was seen in 6% to 19% of adjuvant pump studies at MSKCC, and required biliary stenting in 3% to 8% of patients. Hepatic toxicity can be avoided in a majority of patients by using a dose-reduction algorithm.
68 It is also noteworthy that extent of hepatic resection does not appear to correlate with toxicity from adjuvant HAI and SYS.
69

PERIOPERATIVE CHEMOTHERAPY FOR RESECTABLE LIVER METASTASES
Chemotherapy before surgery, even in those patients with resectable disease, is proposed to increase the complete resection rate, facilitate limited hepatectomies, treat micrometastatic disease, provide a test of chemoresponsiveness, and identify aggressive disease. The EORTC Intergroup trial 40983 randomly assigned patients with resectable disease to perioperative chemotherapy or surgery alone. 70 This trial recruited 364 patients from 78 centers in 11 different countries. A maximum of four liver metastases was allowed and simultaneous resection of primary tumor and liver metastases or patients who had immediate resection for metachronous metastases were not allowed. Patients were randomly assigned to 6 months of perioperative modified FOLFOX4 (3 months before and 3 months postliver resection) or first-line surgery and observation. The primary objective was increased PFS. Median follow-up was 3.9 years. In the perioperative chemotherapy group, there was a 7.3% increase in PFS (from 28.1% to 35.4%) in randomly assigned patients (HR, 0.79; P ϭ .058), further increased to 9.2% in patients undergoing resection (from 33.2% to 42.4%; HR 0.73; 95% CI, 0.55 to 0.97; P ϭ .025; Fig 2) . Rates of complete resection were similar in both arms. Postoperative complications occurred more often after chemotherapy versus surgery alone (25% v 16%; P ϭ .04) and included, biliary fistulae (output higher than 100 mls/d for longer than 10 days: 8% v 4%), hepatic failure (bilirubin higher than 10 mg/d for longer than 3 days: 6% v 3%), and wound infection (3% v 2%). However, all complications were reversible and the incidence of these complications did not differ significantly from other series. 20, 21 Mortality was also similar in both arms. Of the initial 182 patients randomly assigned to perioperative chemotherapy, 79% completed preoperative treatment and 11 patients (6%) did not start treatment; 115 patients (63%) started postoperative protocol chemotherapy and 80 (70%) of these completed planned treatment. The authors concluded that perioperative chemotherapy with modified FOLFOX4 was compatible with major liver resection and reduced the risk of PFS by one fourth in resected patients. OS data are not yet mature. This study has resulted in perioperative chemotherapy becoming the standard for most patients with resectable liver metastases in many centers, and to our knowledge, is the first study to evaluate the combination of surgery and chemotherapy in this setting with adequate statistical power. However, it remains unknown whether the positive effects reported in the treatment arm were related to perioperative or postoperative therapy. In a phase II trial, the Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR) concluded that both postoperative FOLFOX-7 and FOLFIRI (each for 3 months) and perioperative FOLFOX-7 (3 months before and after surgery) were feasible and well-tolerated in patients with resectable liver metastases. 71 This has lead to the phase III Metastatic Irinotecan and Oxaliplatin (MIROX) trial comparing these two strategies (www .clinicaltrials.gov, NCT00268398).
Large studies have shown that the addition of cetuximab to FOLFOX or FOLFIRI in initially unresectable liver metastases can increase resection rates.
17,72 However, to date, there are no randomized data for integrating biologic agents into liver resection strategies. An Austrian group reported a phase II 56-patient trial of perioperative XELOX (oxaliplatin and capecitabine) plus bevacizumab for potentially resectable liver metastases. Response to neoadjuvant chemotherapy was correlated with prolonged PFS (P Ͻ .01) and completion of postoperative chemotherapy also had an independent influence on PFS (P ϭ .04).
73,74 Bevacizumab did not increase postoperative morbidity significantly. Perioperative bevacizumab-containing chemotherapy have been also shown to be feasible in other small studies. 75 The integration of cetuximab into resectable liver metastases algorithms is under investigation in both a randomized phase III trial (www.clinicaltrials.gov, NCT00482222) and a randomized phase II trial (www.clinicaltrials.gov, NCT00438737).
DOES NEOADJUVANT CHEMOTHERAPY PROVIDE MORE OF A BENEFIT THAN ADJUVANT THERAPY?
To date, no trial has clearly proven a role for preoperative (neoadjuvant) chemotherapy. However, expert panels recommend the use of preoperative chemotherapy in both resectable and unresectable liver metastases. 76 Concerns with this approach are outlined in this section and in Table 3 Toxicity from neoadjuvant chemotherapy may result in increased perioperative morbidity and mortality.
78 Hepatic steatosis and sinusoidal injury have been associated with FU, irinotecan, and oxaliplatin.
79-82
Duration of chemotherapy, either pre-or post-liver resection is directly correlated to morbidity and mortality after liver resection, with a treatment period of 3 months pre-and postresection cited as optimal treatment duration. 77, [83] [84] [85] [86] In the EORTC study, complications after preoperative FOLFOX included hepatobiliary toxicity and wound infections. Increased risk of chemotherapy-associated liver injury is also correlated with common conditions like obesity and excessive alcohol intake. 87 In these settings, it may be advisable to resect liver disease first and consider adjuvant chemotherapy afterward.
32
Is response to neoadjuvant therapy before liver resection necessary? If liver metastases are initially unresectable, the answer is yes. 88 However, opinions differ for initially resectable disease. A retrospective study of 111 patients with synchronous resectable disease reported response to neoadjuvant chemotherapy was not related to OS after hepatic resection. Comparing response in three categories (ie, complete response [CR]/partial response, stable disease, or progressive disease), median OS was similar (58 months, 65 months, and 61 months, respectively; P ϭ .98).
89 In a series of 234 patients receiving postoperative HAI and SYS after liver resection, there was no OS advantage for patients receiving neoadjuvant treatment. Median survival was 62 months with neoadjuvant therapy and 115 months with no prior therapy. 90 In contrast, an Austrian group reported a prospective series of 50 patients with resectable liver disease treated with neoadjuvant FOLFOX/XELOX. Multivariate analyses revealed response to chemotherapy correlated with improved recurrence free (P ϭ .002) and OS (P ϭ .017). 91 In larger series, lack of response to neoadjuvant chemotherapy for resectable liver metastases is associated with shorter survival. [92] [93] [94] The M. D. Anderson Cancer Center examined 305 patients who underwent liver resection after preoperative chemotherapy (most presented with resectable disease). Surgical margins and pathologic response were the only independent predictive factors for survival. 95 They also noted that 35% of the total population could not receive postoperative chemotherapy due to protracted recovery times after liver resection.
If patients develop a radiologic CR to preoperative chemotherapy, there is high chance that viable cancer is still present and will be missed at surgery. Benoist et al 96 reported a series of patients with a total of 66 liver metastases that disappeared on computed tomography scan after preoperative chemotherapy. In the 66 sites, viable cancer was present in 12 (80%) at surgery and in situ recurrence in 23 (74%) suggesting that radiologic CR did not mean a true CR. 96 The chance of achieving a true CR in the liver (pathologic CR or durable CR) is increased 6.2 fold (P ϭ .02) with the use of preoperative HAI as reported in retrospective series of 435 patients from MSKCC and other series. 97, 98 Comparing outcomes of neoadjuvant or perioperative strategies with adjuvant strategies is difficult due to population heterogeneity, differences in chemotherapy regimens, methodologies in statistical analysis, and length of follow-up. Table 3 outlines advantages and disadvantages for each strategy.
CONCLUSIONS
Liver resection is an ultimate goal of treatment strategies for liverconfined metastatic CRC. There is a sound rationale for adjuvant therapy after liver resection as many patients experience disease recurrence.
32 Despite this, it has been difficult to show a benefit of adjuvant chemotherapy in this setting. Reasons include: small trials, differences in clinicopathologic variables, [34] [35] [36] 47, 51, 56 and most trials are powered for DFS. 37, 48, 52 Many trials have methodologic problems and do not satisfy standard methodologic quality checklists 99 (ie, patients randomly assigned to the treatment arm are not treated, 49 benefit reported for patients actually treated and not those intended to treat, 48 and long accrual periods using what becomes out-dated chemotherapy may make original end points less meaningful).
37 Lack of randomization in many studies makes results difficult to interpret.
57,58
The sequencing of chemotherapy when liver resection is an option is unclear. Some suggest that resectable liver metastases, without high-risk features, should proceed to surgery first and then consideration given to adjuvant chemotherapy. If high-risk features (ie, bilobar disease, a lesion Ͼ 5 cm) are present, some feel a short course of systemic preoperative chemotherapy (ie, Յ 3 months) is appropriate. The EORTC 40983 trial is an adequately powered prospective study demonstrating an increase in DFS with perioperative systemic chemotherapy in the setting of liver resection. 70 As a result, perioperative chemotherapy is considered a standard option for most patients with resectable liver metastases. Surgical complications and hepatic toxicity may result after preoperative chemotherapy, but in the absence of pre-existing liver disease and with short treatment courses, adverse sequelae can be kept to a minimum. It is not clear if pre-or postoperative therapy or both are needed. Extrapolation from the EORTC trial has also resulted in the use of FOLFOX as adjuvant treatment after liver resection.
Adjuvant systemic FU/LV after resection has shown advantage in retrospective studies, but only an increase in DFS is seen after adjusting for negative factors in prospective adjuvant studies. 11, 12, 37 The addition of irinotecan to bolus and infusional FU/LV did not improve outcome compared to FU/LV alone after liver resection.
38 As yet there are no randomized data for the addition of oxaliplatin to FU/LV as postoperative adjuvant therapy after liver resection. The randomized HAI plus SYS studies used as adjuvant chemotherapy after liver resection that seem to improve outcomes compared with surgery or SYS alone and should also be considered. Three of four studies using HAI as adjuvant therapy after resection report an increased DFS. 48, [52] [53] [54] Large retrospective series of HAI therapy have also confirmed a benefit for adjuvant treatment. 10, 62 It is important to note that caution must be exercised in interpreting such data as institutional bias, and patient selection can overstate the benefit. There are no randomized data supporting the addition of modern systemic agents to HAI therapy, although phase I/II data are promising (Kemeny et al, submitted for publication). 57, 58 In unresectable disease, increasing response rate is important and consideration should be given to modern chemotherapy combined with targeted agents 72, 74 or with HAI. 16 If the disease becomes resectable, 3 to 6 months of adjuvant treatment should follow with a regimen decided on after considering preoperative treatment (ie, if FOLFOX was well-tolerated and produced a response, this regimen should be considered postoperatively). HAI can cause liver toxicity, but with appropriate timing and dose reductions hepatic toxicity is manageable. A sample algorithm of adjuvant chemotherapy for the management of CRC liver metastases is shown in Figure 3 .
What is clear is that patients should be stratified based on CRS and possibly biomarkers (eg, KRAS). The management plan for each patient should be decided by a multidisciplinary team. It may not be possible, or ethically defensible, to perform large randomized adjuvant trials comparing chemotherapy with surgery alone or comparing modern chemotherapy with older regimens. It may be reasonable to extrapolate from adjuvant trials and meta-analyses showing predominantly DFS benefit. Each decision on postoperative chemotherapy should be viewed in context of prior treatment, surgical preference, and individual patient characteristics. 
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